| Composition of Certain Financial Statement Captions |
|
|
|
|
|
|
|
|
|
(In thousands) |
March 31,
2019 |
|
December 31,
2018 |
Accounts receivable, net: |
|
|
|
Accounts receivable |
$ |
146,333 |
|
|
$ |
145,665 |
|
Less: allowance for doubtful accounts |
(1,950 |
) |
|
(1,758 |
) |
|
$ |
144,383 |
|
|
$ |
143,907 |
|
Inventories, net: |
|
|
|
Consumable supplies |
$ |
21,599 |
|
|
$ |
23,264 |
|
Finished products |
18,891 |
|
|
15,259 |
|
Work in-process |
2,851 |
|
|
2,473 |
|
Raw materials |
4,729 |
|
|
4,259 |
|
Less: inventory reserve |
(3,460 |
) |
|
(2,956 |
) |
|
$ |
44,610 |
|
|
$ |
42,299 |
|
Other current assets and prepaid expenses: |
|
|
|
Taxes recoverable |
19,893 |
|
|
15,708 |
|
Other receivables |
(457 |
) |
|
2,368 |
|
Prepaid supplies |
12,200 |
|
|
9,693 |
|
Prepaid insurance |
2,847 |
|
|
3,436 |
|
Other |
4,511 |
|
|
3,847 |
|
|
$ |
38,994 |
|
|
$ |
35,052 |
|
Intangible assets, net: |
|
|
|
Customer relationships |
$ |
445,661 |
|
|
$ |
446,296 |
|
Technologies |
340,648 |
|
|
340,729 |
|
Trade names |
50,413 |
|
|
50,404 |
|
Licenses |
5,766 |
|
|
5,766 |
|
Covenants not to compete |
16,318 |
|
|
16,322 |
|
Product registrations |
7,954 |
|
|
7,861 |
|
Other |
5,533 |
|
|
5,613 |
|
Less: accumulated amortization |
(274,977 |
) |
|
(258,539 |
) |
|
$ |
597,316 |
|
|
$ |
614,452 |
|
Accrued expenses: |
|
|
|
Contract liabilities |
$ |
65,288 |
|
|
$ |
63,503 |
|
Employee benefits |
42,354 |
|
|
45,621 |
|
Clinical trials |
11,996 |
|
|
10,401 |
|
Contingent consideration |
2,375 |
|
|
2,375 |
|
Finance leases short-term |
3,077 |
|
|
3,280 |
|
Milestone payment |
4,919 |
|
|
4,871 |
|
Professional fees |
6,689 |
|
|
7,935 |
|
Other |
80,836 |
|
|
65,527 |
|
|
$ |
217,534 |
|
|
$ |
203,513 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands) |
March 31,
2019 |
|
December 31,
2018 |
Other long-term liabilities: |
|
|
|
Contract liabilities |
$ |
7,708 |
|
|
$ |
27,566 |
|
Line of credit |
— |
|
|
105,198 |
|
Contingent consideration |
26,968 |
|
|
22,162 |
|
Mortgages and other debts payable |
4,322 |
|
|
4,654 |
|
Finance leases long-term |
4,981 |
|
|
5,620 |
|
Other |
34,186 |
|
|
33,768 |
|
|
$ |
78,165 |
|
|
$ |
198,968 |
|
|
| Changes in Goodwill |
The following table summarizes the changes in Goodwill during the three months ended March 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2019 |
(In thousands) |
Balance at January 1 |
|
Foreign exchange and other
|
|
Balance at March 31st |
Pharmaceuticals |
|
|
|
|
|
CURNA |
$ |
4,827 |
|
|
$ |
— |
|
|
$ |
4,827 |
|
EirGen |
85,245 |
|
|
(1,683 |
) |
|
83,562 |
|
FineTech |
— |
|
|
— |
|
|
— |
|
OPKO Chile |
4,614 |
|
|
91 |
|
|
4,705 |
|
OPKO Biologics |
139,784 |
|
|
— |
|
|
139,784 |
|
OPKO Health Europe |
7,545 |
|
|
(149 |
) |
|
7,396 |
|
OPKO Renal |
2,069 |
|
|
— |
|
|
2,069 |
|
Transition Therapeutics |
3,323 |
|
|
70 |
|
|
3,393 |
|
|
|
|
|
|
|
Diagnostics |
|
|
|
|
|
BioReference |
401,821 |
|
|
— |
|
|
401,821 |
|
OPKO Diagnostics |
17,977 |
|
|
— |
|
|
17,977 |
|
OPKO Lab |
32,988 |
|
|
— |
|
|
32,988 |
|
|
$ |
700,193 |
|
|
$ |
(1,671 |
) |
|
$ |
698,522 |
|
|